Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease

British Journal of Pharmacology

Volumn 155, Issue 7, 2008, Pages 1085-1092

  Grip, O ^a,d   Janciauskiene, S ^b   Bredberg, A ^c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atorvastatin; Biomarkers; Crohn's disease; Immunopharmacology

Indexed keywords

ATORVASTATIN; AUTACOID; C REACTIVE PROTEIN; CALGRANULIN; CD14 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; SOLUBLE CD14 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLATULENCE; HUMAN; HUMAN CELL; IMPOTENCE; MALE; MONOCYTE; MUCOSA INFLAMMATION; MUSCLE FATIGUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PRURITUS; QUANTITATIVE ASSAY; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD14; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CHEMOKINE CCL8; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MONOCYTES; PYRROLES; RECEPTORS, CCR2; RECEPTORS, CHEMOKINE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 56749161704     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.369     Document Type: Article

References (41)

1. Arias MA, Rey Nores JE, Vita N, Stelter F, Borysiewicz LK, Ferrara P et al. (2000). Cutting edge: human B cell function is regulated by interaction with soluble CD14: opposite effects on IgG1 and IgE production. J Immunol 164: 3480-3486.
2. Banks C, Bateman A, Payne R, Johnson P, Sheron N (2003). Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 199: 28-35.
3. Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C (2004). CD14 is an acute-phase protein. J Immunol 172: 4470-4479.
4. Berstad A, Arslan G, Folvik G (2000). Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol 35: 64-69.
5. Best WR, Becktel JM, Singleton JW, Kern Jr F (1976). Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70: 439-444.
6. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G et al. (2007). Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J 153: 881-888.
7. Davidson MH, Robinson JG (2007). Safety of aggressive lipid management. J Am Coll Cardiol 49: 1753-1762.
8. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P et al. (2001). In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21: 1327-1332.
9. Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gomez-Campdera F, Vega A et al. (2006). Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 17: S231-S235.
10. Grage-Griebenow E, Flad HD, Ernst M (2001). Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol 69: 11-20.
11. Grip O, Bredberg A, Lindgren S, Henriksson G (2007). Increased subpopulations of CD16(+) and CD56(+) blood monocytes in patients with active Crohn's disease. Inflamm Bowel Dis 13: 566-572.
12. Grip O, Janciauskiene S, Lindgren S (2004). Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin. Inflamm Bowel Dis 10: 193-200.
13. Hackam DG, Mamdani M, Li P, Redelmeier DA (2006). Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 367: 413-418.
14. Hattar K, Fink L, Fietzner K, Himmel B, Grimminger F, Seeger Wet al. (2001). Cell density regulates neutrophil IL-8 synthesis: role of IL-1 receptor antagonist and soluble TNF receptors. J Immunol 166: 6287-6293.
15. Jahovic N, Gedik N, Ercan F, Sirvanci S, Yuksel M, Sener G et al. (2006). Effects of statins on experimental colitis in normocholesterolemic rats. Scand J Gastroenterol 41: 954-962.
16. Jain MK, Ridker PM (2005). Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4: 977-987.
17. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD et al. (2008). Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol 28: 142-147.
18. Komatsu M, Kobayashi D, Saito K, Furuya D, Yagihashi A, Araake H et al. (2001). Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 47: 1297-1301.
19. Konduracka E, Galicka-Latala D, Cieslik G, Rostoff P, Fedak D, Sieradzki J et al. (2007). Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension. Diabetes Obes Metab Oct 17 [Epub ahead of print].
20. Konikoff MR, Denson LA (2006). Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 12: 524-534.
21. Kwak B, Mulhaupt F, Myit S, Mach F (2000). Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-1402.
22. Lee JY, Kim JS, Kim JM, Kim N, Jung HC, Song IS (2007). Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol 7: 241-248.
23. Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al-Lazikani B et al. (2006). Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367: 668-678.
24. Martinez-Borra J, Lopez-Larrea C, Gonzalez S, Fuentes D, Dieguez A, Deschamps EM et al. (2002). High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 97: 2350-2356.
25. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I et al. (2004). Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363: 2015-2021.
26. Moriarty PM, Gibson CA, Shih J, Matias MS (2001). C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 158: 495-498.
27. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1993). Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34: 1705-1709.
28. Nicholls S, Stephens S, Braegger CP, Walker-Smith JA, MacDonald TT (1993). Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol 46: 757-760.
29. Pastor Rojo O, Lopez San Roman A, Albeniz Arbizu E, de la Hera Martinez A, Ripoll Sevillano E, Albillos Martinez A (2007). Serum lipopolysaccharide- binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis 13: 269-277.
30. Rossol M, Meusch U, Pierer M, Kaltenhauser S, Hantzschel H, Hauschildt S et al. (2007). Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J Immunol 179: 4239-4248.
31. Sasaki M, Bharwani S, Jordan P, Joh T, Manas K, Warren A et al. (2003). The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextransulfate induced colitis. J Pharmacol Exp Ther 305: 78-85.
32. Schinzari F, Armuzzi A, De Pascalis B, Mores N, Tesauro M, Melina D et al. (2008). Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease. Clin Pharmacol Ther 83: 70-76.
33. Solem CA, Loftus Jr EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ (2005). Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 11: 707-712.
34. Spoettl T, Hausmann M, Klebl F, Dirmeier A, Klump B, Hoffmann J et al. (2007). Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis 13: 727-732.
35. Stewart CC, Stewart SJ (2001). Cell preparation for the identification of leukocytes. Methods Cell Biol 63: 217-251.
36. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I (2000). Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119: 15-22.
37. Tlaskalova-Hogenova H, Tuckova L, Stepankova R, Hudcovic T, Palova-Jelinkova L, Kozakova H et al. (2005). Involvement of innate immunity in the development of inflammatory and autoimmune diseases. Ann N Y Acad Sci 1051: 787-798.
38. van Leuven SI, Hezemans R, Levels JH, Snoek S, Stokkers PC, Hovingh GK et al. (2007). Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res 48: 2640-2646.
39. Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, Steffens S et al. (2006). Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 188: 51-58.
40. Vermeire S, Van Assche G, Rutgeerts P (2006). Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55: 426-431.
41. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S et al. (2004). Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363: 1607-1608.